Pharmaceutical Drugs Coverage

Androgenetic Alopecia Treatment Market Definition And Segments

Androgenetic alopecia, also known as male-pattern baldness or female-pattern hair loss, is a common form of hair loss in both men and women. It is characterized by a progressive thinning of the hair, typically starting with a receding hairline in men and diffuse thinning over the crown in women. This condition is influenced by genetic factors and the presence of androgens, particularly dihydrotestosterone (DHT). The main types of androgenetic alopecia treatments are pharmaceuticals and devices. A pharmaceutical is a substance utilized in healthcare, typically a medicinal drug or chemical compound. The different types of medications are prescription and over-the-counter which are used by both males and females. It is used by several end-user industries including homecare settings, dermatology, clinics, and others. The androgenetic alopecia treatment market covered in this report is segmented – 1) By Treatment Type: Pharmaceutical, Device 2) By Medication Type: Prescription, Over-The-Counter 3) By Gender: Male, Female 4) By End-User: Homecare Settings, Dermatology, Clinics, Other End-Users The androgenetic alopecia treatment market size has grown strongly in recent years. It will grow from $2.13 billion in 2023 to $2.29 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to emphasis on improving patient outcomes and quality of life, increase in the geriatric population, increasing healthcare expenditure. The androgenetic alopecia treatment market size is expected to see strong growth in the next few years. It will grow to $3.07 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising incidence of hair loss, prevalence of chronic diseases such as cancer, polycystic ovary syndrome (PCOS), and rheumatoid arthritis, demand for effective solutions to address hair loss concerns. Major trends in the forecast period include partnerships, product approvals, investments, research and developments.

Rising Hair Loss Cases Drive Growth In The Androgenetic Alopecia Treatment Market

The rising hair loss cases are expected to propel the growth of the androgenetic alopecia treatment market going forward. Hair loss or alopecia refers to the partial or complete loss of hair from the scalp or other body parts. Hair loss cases are related to nutritional deficiencies, hormonal changes, genetics, and increased stress. Androgenetic alopecia treatments work through various mechanisms, including hormonal regulation, follicle stimulation, and surgical restoration, to manage hair loss and promote regrowth. For instance, in March 2022, according to an article by the Hair Society, a US-based full-service professional organization, hair loss affected about 21 million women and 35 million men globally. Moreover, in 2024, according to the National Health Service, a UK-based government agency, approximately 8 million women and 6.5 million men are affected by hair loss in the UK. Additionally, more than 650,000 hair transplants are carried out each year. Therefore, rising hair loss cases drive the androgenetic alopecia treatment market. Major companies operating in the androgenetic alopecia treatment market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Eli Lilly and Company, Daiichi-Sankyo Co. Ltd., Sun Pharmaceutical Industries Ltd., Allergan Plc, Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Cipla Limited, Fagron Inc., Vitabiotics Ltd., Cosmo Pharmaceuticals NV, Aclaris Therapeutics Inc., Curallux LLC, PureTech Health, Technoderma Medicines Inc., Theradome Inc., Lexington International, HCell Inc., Follica Inc., Ranbaxy Laboratories Ltd., Apira Science Inc., Freedom Laser Therapy Inc., Histogen Inc.

Innovative Developments In Androgenetic Alopecia Treatment With FDA Approvals And New Drug Options Lead The Way

Major companies operating in the androgenetic alopecia treatment market are developing innovative drug options for addressing hair loss through mechanisms such as promoting hair follicle regeneration, inhibiting hormones that cause hair loss, and using novel delivery systems like topical treatments and oral medications. For instance, in June 2023, Pfizer Inc., a US-based healthcare company, announced the FDA approval of LITFULO (ritlecitinib), a once-daily oral treatment for individuals 12 years of age and older with severe alopecia areata. LITFULO is a kinase inhibitor that inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) family of kinases. The FDA approval was based on the ALLEGRO Phase 2b/3 trial, where 23% of patients treated with LITFULO 50mg achieved 80% or more scalp hair coverage after six months compared to 1.6% with placebo. The solution offers a new option for individuals struggling with substantial hair loss, addressing a previously unmet need to treat alopecia areata.

Teva Pharmaceutical Industries Broadens Portfolio With Marksans Pharma Acquisition

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired the manufacturing facility from Tevapharm India for an undisclosed amount. This strategic move allowed Marksans Pharma to double its existing Indian manufacturing capacity and expand its product range to include tablets, capsules, ointments, liquids, and creamsTeva Pharmaceuticals is an Israel-based company that provides treatment for androgenetic alopecia. North America was the largest region in the androgenetic alopecia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgenetic alopecia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the androgenetic alopecia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The androgenetic alopecia treatment market consists of sales of microneedling devices, hair growth vitamins, and supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The androgenetic alopecia treatment market research report is one of a series of new reports from The Business Research Company that provides androgenetic alopecia treatment market statistics, including androgenetic alopecia treatment industry global market size, regional shares, competitors with an androgenetic alopecia treatment market share, detailed androgenetic alopecia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the androgenetic alopecia treatment industry. This androgenetic alopecia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anticoccidial Drugs Market Definition And Segments

Anticoccidial drugs are a class of medications used to prevent and treat coccidiosis, a parasitic disease of the intestinal tract caused by protozoa of the genus Eimeria. These drugs work by inhibiting various stages of the coccidia life cycle, controlling the infection, and preventing the severe intestinal damage and related symptoms associated with the disease. Anticoccidial drugs are commonly used in veterinary medicine, particularly poultry, to enhance health and productivity by managing this widespread and economically significant condition. The main drug classes of anticoccidial drugs are ionophores, antibiotics, sulphonamides, chemical derivatives, and others. Ionophores are a type of anticoccidial drug that disrupts the growth and reproduction of coccidia parasites by affecting ion transport across cell membranes. Various drug actions include coccidiostatic and coccidiocidal for a variety of applications, such as poultry, swine, fish, cattle, and companion animals, through different distribution channels, including veterinary hospitals, retail pharmacies, and others. The anticoccidial drugs market covered in this report is segmented – 1) By Drug Class: Ionophore, Antibiotic, Sulphonamides, Chemical Derivative, Other Drug Classes 2) By Drug Action: Coccidiostatic, Coccidiocidal 3) By Application: Poultry, Swine, Fish, Cattle, Companion Animals 4) By Distribution Channel: Veterinary Hospitals, Retail Pharmacy, Other Distribution Channels The anticoccidial drugs market size has grown strongly in recent years. It will grow from $1.19 billion in 2023 to $1.27 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increased incidence of coccidiosis globally, increased adoption of pet animals, high prevalence of coccidiosis, economic impact, and increased safety concerns about food and health of animals. The anticoccidial drugs market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the growing number of veterinary healthcare, the rising prevalence of coccidiosis in animals, the increasing use of synthetic drugs, the growing demand for feed additives, and increasing livestock production. Major trends in the forecast period include the surge in demand driven by emerging coccidiosis strains, a shift towards natural and alternative treatment methods, increased regulatory scrutiny prompting innovation, rising consumer preferences for antibiotic-free poultry products, advancements in drug delivery technologies, heightened focus on preventive healthcare measures, and expanding applications in aquaculture and companion animal sectors.

Impact Of Growing Demand For Meat Proteins In The Anticoccidial Drug Market

The growing demand for meat proteins is expected to propel the growth of the anticoccidial drug market going forward. Meat proteins are naturally present in animal flesh, comprising various amino acids essential for various bodily functions. The rising demand for meat proteins is due to population growth, increasing disposable income, urbanization, and changing dietary preferences toward protein-rich foods. Anticoccidial drugs are essential tools in modern livestock farming. They help maintain the health and productivity of animals, ensuring that farmers can meet the growing demand for meat proteins efficiently and sustainably. For instance, in July 2021, according to the report published by the Organization for Economic Co-operation and Development (OECD), a France-based intergovernmental organization, and the Food and Agriculture Organization, an Italy-based specialized agency, global consumption of meat proteins is forecast to surge by 14% by 2030, where availability of protein from various meat sources is expected to grow as beef by 5.9%, pork by 13.1%, poultry by 17.8%, and sheep meat by 15.7%. Therefore, the growing demand for meat proteins is driving the growth of the anticoccidial drug market.

Poultry Farming Surge Drives Anticoccidial Drug Market Growth

The rise in poultry farming is expected to propel the growth of the anticoccidial drug market going forward. Poultry farming refers to raising domesticated birds, such as chickens, turkeys, ducks, and geese, to produce meat, eggs, and feathers. The rise in poultry farming is due to increasing demand for protein, improved farming techniques, and the expansion of global trade. Anticoccidial drugs are often added to poultry feed or water as a preventive measure to protect the birds from coccidiosis during the early and most vulnerable stages of growth. For instance, in June 2023, according to the USDA Economic Research Service, a US-based government administration, the poultry sector's total sales reached $76.9 billion in 2022, a 67% increase from the previous year. Therefore, the rise in poultry farming is driving the growth of the anticoccidial drug market. Major companies operating in the anticoccidial drugs market are Johnson & Johnson, Merck and Co. Inc., Bayer AG, Novartis AG, Eli Lilly and Company Ltd., Boehringer Ingelheim GmbH, Zoetis Inc., Elanco Animal Health Incorporated, Intas Pharmaceuticals Ltd., Ceva Santé Animale S.A., Virbac S.A., Phibro Animal Health Corporation, Vetoquinol SA, Alpharma BVBA, Kepro B.V., Kemin Industries Inc., Tianjin Ringpu Bio-Technology Co. Ltd., Hester Biosciences Limited, Huvepharma AD, Biovet S.A., Lallemand Animal Nutrition, HIPRA, Impextraco NV, Venkateshwara Hatcheries Pvt Ltd

Innovative Zoalene-Based Solutions In Anticoccidial Drug Development

Major companies operating in the anticoccidial drugs market focus on developing innovative solutions, such as zoalene-based solutions, to enhance efficacy, minimize resistance development, and address emerging challenges in poultry and livestock management. A zoalene-based solution includes zoalene as its active ingredient and is utilized to combat coccidiosis in poultry. For instance, in May 2021, Elanco Animal Health Incorporated, a US-based pharmaceutical company, introduced ZoaShielda, a zoalene-based solution designed to control coccidiosis in poultry effectively. It offers poultry producers a flexible and reliable product suitable for various seasons and operations. It provides the expected reliability for managing coccidiosis while offering operational flexibility to producers. North America was the largest region in the anticoccidial drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anticoccidial drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anticoccidial drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The anticoccidial drugs market consist of sales of semduramicin, monensin, lasalocid, salinomycin, decoquinate, amprolium, clopidol, and sulfachloropyrazine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The anticoccidial drugs market research report is one of a series of new reports from The Business Research Company that provides anticoccidial drugs market statistics, including anticoccidial drugs industry global market size, regional shares, competitors with a anticoccidial drugs market share, detailed anticoccidial drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anticoccidial drugs industry. This anticoccidial drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Autologous Stem Cell And Non-Stem Cell Based Therapies Market Definition And Segments

Autologous stem cell and non-stem cell-based therapies refer to treatments that use a patient's own cells to repair, replace, or regenerate damaged tissues and organs. Autologous stem cell therapies involve extracting stem cells from the patient, expanding or modifying them, and then reinfusing them to promote healing and regeneration. Non-stem cell-based therapies use other types of cells, such as immune cells or tissue-specific cells, to achieve similar therapeutic goals. These personalized approaches aim to minimize the risk of immune rejection and enhance the efficacy of treatments for various conditions, including cancer, autoimmune diseases, and degenerative disorders. The main types of autologous stem cell and non-stem cell based therapies are autologous stem cells, autologous non-stem cells, and others. Autologous stem cells are cells extracted from the patient's own body and employed in medical therapies to heal damaged tissue or organs. They are used for various applications including cancer, neurodegenerative disorders, cardiovascular disease, orthopedic diseases, and others by hospitals, ambulatory surgical centers, research facilities, and others. The autologous stem cell and non-stem cell based therapies market covered in this report is segmented – 1) By Type: Autologous Stem Cells, Autologous Non-Stem Cells, Other Types 2) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, Other Applications 3) By End-User: Hospitals, Ambulatory Surgical Centers, Research Facilities, Other End Users The autologous stem cell and non-stem cell based therapies market size has grown rapidly in recent years. It will grow from $8.58 billion in 2023 to $9.96 billion in 2024 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increased prevalence of cancer and diabetes, increased numbers of geriatric individuals, growing healthcare awareness, rise in research and development activities, increased numbers of clinical trials, Increased regulatory approval. The autologous stem cell and non-stem cell based therapies market size is expected to see rapid growth in the next few years. It will grow to $18.16 billion in 2028 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to rising prevalence of targeted diseases, an increasing geriatric population, rising prevalence of neurodegenerative diseases, growing number of cancer cases, increasing demand for skin transplantation, increasing awareness about regenerative medicine, collaborations and partnerships among key players, improving reimbursement for approved therapies. Major trends in the forecast period include the integration of artificial intelligence and machine learning, development of off-the-shelf allogeneic stem cell products, expansion of reimbursement policies, adoption of novel biomaterials, advancements in cell manufacturing technologies, adoption of autologous stem cell therapies, integration of gene editing technologies.

Personalized Therapies Driving Growth In Autologous And Non-Stem Cell Therapies Market

The demand for personalized therapies is expected to propel the growth of the autologous stem cell and non-stem cell-based therapies market going forward. Personalized therapies are medical treatments designed to maximize benefits and minimize adverse effects based on a patient's unique genetics, lifestyle, and preferences. Personalized therapies are on the rise owing to several factors, such as advances in genetics and technology that allow for more precise and effective treatments with fewer side effects, increased patient demand for tailored care, and the potential for healthcare cost savings. Personalized therapies improve the use of autologous stem cell and non-stem cell-based treatments by customizing them to a person's unique genetic and health characteristics, leading to better results and fewer complications. For instance, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2022, the approval of 12 new personalized medicines represented approximately 34% of all newly approved therapies, indicating a substantial increase from previous years. Therefore, the demand for personalized therapies drives the autologous stem cell and non-stem cell-based therapies market. Major companies operating in the autologous stem cell and non-stem cell based therapies market are Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck & Co. Inc., Stemcell Technologies Inc., Dendreon Corporation, Vericel Corporation, Sangamo Therapeutics Inc., NEOSTEM, Orgenesis Inc., Adaptimmune Therapeutics, Stempeutics Research Pvt Ltd., MEDIPOST, Castle Creek Biosciences Inc., BrainStorm Cell Limited, Athersys Inc., Cytori Therapeutics Inc., Opexa Therapeutics, Gamida Cell, Regen BioPharma Inc., RepliCel Life Sciences, InGeneron Inc., BioCardia Inc., ReNeuron Group

Advancements In Autologous T-cell Immunotherapy

Major companies in the autologous stem cell and non-stem cell-based therapies market are developing tumor-derived autologous T cell immunotherapy to enhance personalized cancer treatment approaches. Tumor-derived autologous T cell immunotherapy works by extracting T cells from a patient's tumor, expanding and activating them in the lab, and reinfusing them into the patient to enhance the immune system's ability to target and destroy cancer cells specifically. For instance, in February 2024, Iovance Biotherapeutics, a US-based biotechnology company, received accelerated approval from the Food and Drug Administration, a US-based federal agency, for Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of adult patients with melanoma. Lifileucel is a tumor-derived autologous T-cell immunotherapy. It comprises a patient's naturally occurring immune cells called tumor-infiltrating lymphocytes (TILs). This allows the patient's immune system to recognize and attack the cancer more effectively.

Metcela Inc. Acquires Japan Regenerative Medicine Co. Ltd. To Strengthen Cardiac Therapy

In April 2022, Metcela Inc., a Japan-based biotechnology company, acquired Japan Regenerative Medicine Co. Ltd. (JRM) for an undisclosed amount. Through this acquisition, Metcela Inc. aims to add an autologous cell product for pediatric congenital heart disease and foster synergies in manufacturing and sales systems for a broad range of cardiac therapies. Japan Regenerative Medicine Co. Ltd. (JRM) is a Japan-based company developing regenerative medicine therapies for pediatric congenital heart diseases and services related to stem cell therapy. North America was the largest region in the autologous stem cell and non-stem cell based therapies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous stem cell and non-stem cell based therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the autologous stem cell and non-stem cell based therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The autologous stem cell and non-stem cell-based therapies market consists of revenues earned by entities by providing services such as patient evaluation, cell collection and processing, genetic modification, quality control, cell storage, infusion, post-treatment monitoring, regulatory compliance, and patient support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autologous stem cell and non-stem cell-based therapies market also includes sales of platelet-rich plasma (PRP) therapy, autologous fibroblast injection, autologous dendritic cell therapy, and tumor-derived autologous T cell immunotherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The autologous stem cell and non-stem cell based therapies market research report is one of a series of new reports from The Business Research Company that provides autologous stem cell and non-stem cell based therapies market statistics, including the autologous stem cell and non-stem cell based therapies industry global market size, regional shares, competitors with autologous stem cell and non-stem cell based therapies market share, detailed autologous stem cell and non-stem cell based therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the autologous stem cell and non-stem cell based therapies industry. These autologous stem cell and non-stem cell based therapies market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Biguanides Market Definition And Segments

Biguanides refer to a group of medications primarily used to treat type 2 diabetes. They help lower blood sugar levels by reducing the amount of sugar produced by the liver and improving the body's response to insulin. These medications are also used to treat polycystic ovary syndrome (PCOS) and other metabolic disorders. The main types of biguanides are metformin, phenformin, and others. Metformin is a widely used biguanide medication that is used to treat type 2 diabetes by lowering blood sugar levels. Various dosage forms, including tablets and oral solutions in different formulations, such as immediate-release and extended-release, are provided through a variety of distribution channels, which include hospital pharmacies, retail pharmacies, and online pharmacies. The biguanides market covered in this report is segmented – 1) By Type: Metformin, Phenformin, Other Types 2) By Dosage Form: Tablets, Oral Solutions 3) By Formulation: Immediate Release, Extended Release 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The biguanides market size has grown steadily in recent years. It will grow from $4.79 billion in 2023 to $4.96 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to a rise in demand for oral hypoglycemic drugs, growth in the geriatric population, rise in obesity rates, and increased awareness about diabetes management. The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.76 billion in 2028 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to the growing adoption of combination therapies, advancements in drug delivery technologies, increasing investment in research and development, rising healthcare expenditure, and expanding applications in the treatment of polycystic ovary syndrome. Major trends in the forecast period include increasing focus on developing extended-release formulations, growing preference for fixed-dose combination therapies, expanding applications in oncology, and the emergence of novel biguanides with improved efficacy and safety profiles.

Impact Of Rising Diabetes Prevalence On Biguanides

The rise in diabetes is expected to propel the growth of the biguanides market going forward. Diabetes refers to a chronic metabolic disorder characterized by high levels of blood sugar (glucose) resulting from the body's inability to produce enough insulin. Rising diabetes is driven by several factors, including lifestyle changes, population aging, genetic predisposition, improved diagnosis, and environmental influences. Biguanides, such as metformin, mitigate diabetes by improving insulin sensitivity, reducing glucose production in the liver, and lowering blood sugar levels in individuals with type 2 diabetes. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported. Therefore, the rising prevalence of diabetes is driving the growth of the biguanides market. Major companies operating in the biguanides market are Cardinal Health Inc., Pfizer Inc., Merck And Co Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceuticals Company Limited, Novo Nordisk A/S, Viatris Inc., Daiichi Sankyo Company Limited, Wanbury Ltd., Boehringer Ingelheim International GmbH, Intas Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Shionogi & Co Ltd., Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Apotex Inc., Torrent Pharmaceuticals Limited, Panacea Biotech Ltd., Auro Laboratories Limited

Advancements In Extended-Release Biguanides For Enhanced Diabetes Management

Major companies operating in the biguanide market are focused on developing advanced solutions, such as extended-release biguanide drugs, to improve patient compliance, enhance therapeutic efficacy, and reduce side effects. An extended-release biguanide is a medication formulated to slowly release its active component, ensuring consistent blood levels and better glycemic control for diabetes patients, thereby improving adherence to the treatment. For instance, in August 2023, Dr. Reddy’s Laboratories, an India-based biotechnology company, launched saxagliptin and metformin hydrochloride extended-release drugs. This is a generic version of KOMBIGLYZE XR, approved by the US Food and Drug Administration (USFDA), which combines saxagliptin, a DPP-4 inhibitor, with metformin, a biguanide. It is designed to enhance glycemic control in adults with type 2 diabetes mellitus and is intended for use alongside diet and exercise. The extended-release formulation helps improve patient adherence and efficacy.

Lupin Strengthens Diabetes Portfolio With Boehringer Ingelheim Acquisition

In August 2023, Lupin, an India-based biopharmaceutical company, acquired diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed amount. Through this acquisition, Lupin continues to offer a wide portfolio of products to enable access to medication and consolidate its position in the anti-diabetes segment. Boehringer Ingelheim is a Germany-based biopharmaceutical company dedicated to the research, development, and production of therapies for both human and veterinary medicine. Asia-Pacific was the largest region in the biguanides market in 2023. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The biguanides market research report is one of a series of new reports from The Business Research Company that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer Supportive Care Drugs Market Definition And Segments

Cancer supportive care drugs are essential in managing the side effects and symptoms associated with cancer treatments, significantly improving patients' quality of life. These medications address issues such as pain, nausea, anemia, and psychological stress, helping patients better tolerate their cancer therapies. By providing comprehensive symptom relief, supportive care drugs enable patients to maintain their strength and well-being throughout their treatment journey. The main types of cancer supportive care drugs are erythropoiesis stimulating agents, granulocyte colony stimulating factors, antiemetics, bisphosphonates, opioids, nonsteroidal anti-inflammatory drugs, and others. Erythropoiesis-stimulating agents (ESAs) are a class of drugs that stimulate the production of red blood cells (erythropoiesis) in the bone marrow. They are used for various applications include breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others distributed through various channels including hospital pharmacies, retail pharmacies, online pharmacies, specialty clinics, and others. The cancer supportive care drugs market covered in this report is segmented – 1) By Type: Erythropoiesis Stimulating Agents, Granulocyte Colony Stimulating Factors, Antiemetics, Bisphosphonates, Opioids, Nonsteroidal Anti Inflammatory Drugs, Other Types 2) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Other Channels The cancer supportive care drugs market size has grown steadily in recent years. It will grow from $19.93 billion in 2023 to $20.83 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to rising geriatric population, increasing prevalence of chemotherapy, growing demand for antiemetics, growing preference for online pharmacies and drug stores, increasing awareness of supportive care, increasing adoption of personalized medicine, growing emphasis on palliative care. The cancer supportive care drugs market size is expected to see grown steadily in the next few years. It will grow to $24.97 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to rising awareness about adverse effects of cancer treatment, growing cases of breast cancer among females, the availability of specific medication plans, demand for online doctor consultations, an improved supply chain in the pharmaceutical sector, increasing the population of cancer survivors. Major trends in the forecast period include advancements in targeted therapies, integration of biobehavioral interventions, implementation of survivorship care plans, integration of nutritional support, advancements in pain management strategies, implementation of symptom monitoring platforms.

Rising Cancer Survival Rates Drive Growth In The Cancer Supportive Care Drugs Market

The improved survival rate for cancer patients is expected to propel the growth of the cancer supportive care drugs market going forward. Cancer survival rate refers to the percentage of people who survive a certain type of cancer for a specific amount of time, typically five years, after being diagnosed. Survival rates for cancer patients are primarily driven by early detection, advances in treatment, access to quality healthcare, the patient's overall health, the type and stage of cancer, and socioeconomic factors. Cancer supportive care drugs help improve cancer survival rates by managing side effects such as pain, nausea, and anemia, enabling patients to better tolerate their treatments and complete their full course of therapy, which can lead to improved outcomes. For instance, as of January 2022, the National Cancer Institute, a US-based government agency, projects that the number of cancer survivors will rise by 24.4% over the next ten years, reaching 22.5 million by 2032. Therefore, the improved survival rate of cancer patients is driving the cancer supportive care drugs market. Major companies operating in the cancer supportive care drugs market are Pfizer Inc., Johnson & Johnson, Merck, AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, F Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc., Fagron Group, Heron Therapeutics Inc., Athenex Inc., Acrotech Biopharma LLC

Development of Combination Therapies in the Cancer Support Care Drugs Market

Major companies operating in the cancer support care drugs market are developing combination therapies to address the complexity and challenges of cancer treatment. Combination therapies involve the strategic use of two or more therapeutic agents to target different aspects of cancer growth and survival, aiming to achieve deeper and more durable responses compared to monotherapy. For instance, in November 2023, Merck, a US-based pharmaceutical company received approval from the Food and Drug Administration, a US-based federal agency, for KEYTRUDA, an anti-PD-1 therapy, in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). The combination therapy showed promising results in improving overall survival and providing a new treatment option for patients with this challenging condition.

Johnson & Johnson's Strategic Acquisition Of Ambrx Biopharma To Bolster Oncology Capabilities

In March 2024, Johnson & Johnson, a US-based pharmaceutical company acquired Ambrx Biopharma Inc. for $2 billion. The acquisition enhances Johnson & Johnson's capabilities in the design and development of targeted oncology therapeutics, in the area of cancer supportive care drugs. This strategic move underscores Johnson & Johnson's commitment to expanding its oncology portfolio, especially in prostate cancer research, and to strengthening its capabilities in developing next-generation antibody-drug conjugates (ADCs). Ambrx Biopharma Inc. is a US-based biotechnology company developing cancer supportive care drugs including next-generation antibody drug conjugates (ADCs). North America was the largest region in the cancer supportive care drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer supportive care drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The cancer supportive care drugs market consists of the sale of analgesics, hematopoietic growth factors, bone modifying agents, corticosteroids, appetite stimulants, anti-diarrheal and laxatives, anti-anxiety and antidepressant medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cancer supportive care drugs market research report is one of a series of new reports from The Business Research Company that provides cancer supportive care drugs market statistics, including cancer supportive care drugs industry global market size, regional shares, competitors with a cancer supportive care drugs market share, detailed cancer supportive care drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cancer supportive care drugs industry. This cancer supportive care drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell Banking Outsourcing Market Definition And Segments

Cell banking outsourcing refers to the practice of contracting external organizations to establish, maintain, and manage repositories of cell lines crucial for various applications in biotechnology and pharmaceutical industries, such as drug discovery and biomanufacturing. It ensures that cells are handled, stored, and maintained under standardized conditions, ensuring consistency and reliability. The main types of cell banking outsourcing include master cell banking, working cell banking, and viral cell banking. Master cell banking (MCB) refers to a stock of well-characterized cells that are derived from a single clone and are intended to serve as the starting material for the production of therapeutic products, such as biologics or cell therapies. Various types of cells are included, such as stem cell banking and non-stem cell banking, for several phases, including bank storage, bank characterization and testing, and bank preparation. The cell banking outsourcing market covered in this report is segmented – 1) By Type: Master Cell Banking, Working Cell Banking, Viral Cell Banking 2) By Cell Type: Stem Cell Banking, Non-Stem Cell Banking 3) By Phase: Bank Storage, Bank Characterization And Testing, Bank Preparation The cell banking outsourcing market size has grown rapidly in recent years. It will grow from $9.76 billion in 2023 to $11.19 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to the rise in the prevalence of chronic diseases, the increased number of government initiatives, regulatory support and guidelines, and the increase in the establishment of banking services. The cell banking outsourcing market size is expected to see rapid growth in the next few years. It will grow to $19.51 billion in 2028 at a compound annual growth rate (CAGR) of 14.9%. The growth in the forecast period can be attributed to rising adoption of cellular products, growing demand for monoclonal antibodies, increasing adoption of stem cell therapies, rising geriatric population, and growing dependency on cell-based therapies. Major trends in the forecast period include product innovations, technological advancements, investments in research and development, and the collaboration between biotech companies and specialized cell banking services.

Driving Growth Of Cell Banking Outsourcing Market Amid Rising Burden Of Chronic Diseases

The rise in the burden of chronic diseases is expected to propel the growth of the cell banking outsourcing market going forward. Chronic diseases are long-lasting conditions that typically develop gradually and persist over an extended period. The rising prevalence of chronic diseases can be attributed to a combination of various factors, including lifestyle changes, aging populations, and genetic predispositions. Cell banking outsourcing plays a valuable role in advancing research and development efforts aimed at addressing chronic diseases by providing access to expertise, resources, and infrastructure that may not be available in-house. For instance, in July 2023, according to the Department of the Treasury, an Australia-based national treasury and financial department, in 2020–21, nearly half of Australians of all ages (46.6%) had one or more chronic diseases, and almost one in five (18.6%) had two or more chronic conditions. Therefore, the rise in the burden of chronic diseases is driving the growth of the cell banking outsourcing market. Major companies operating in the cell banking outsourcing market are LabCorp Drug Development, SGS Life Sciences, Lonza Group Ltd., WuXi AppTec, Charles River Laboratories, Sigma-Aldrich Co. Ltd., Covance Inc., Global Stem Inc., LifeCell, Cryoviva India, Sartorius AG, Bio Reliance, CordLife, Reliance Life Sciences, Cryo-Cell International Inc., Toxikon Corp., Cleancells, Clean Biologics, Texcell, PX’Therapeutics SA, Goodwin Biotechnology Inc., Transcell Biolife Pvt Ltd., Perfectus Biomed Limited, BioStorage Technologies Inc.

Innovative Single Cell Potency Characterization Platform Revolutionizes Cell Therapy Research

Major companies operating in the cell banking outsourcing market are focusing on developing technologically advanced solutions, such as single-cell potency characterization platforms, to provide precise and detailed analysis of individual cell potency. A single-cell potency characterization platform is a sophisticated technology or set of methodologies designed to assess and measure the potency and functional capabilities of individual cells within a cell population. For instance, in January 2024, Cellply Srl, an Italy-based biotechnology company, launched VivaCyte, its flagship product and an end-to-end single-cell potency characterization platform that integrates potency analysis and immunophenotyping to streamline cell therapy research and development. VivaCyte is a fully automated, standalone platform with single-cell resolution, designed to reduce development times, costs, and risks by characterizing the complex functionality and mechanism of action of potential cellular immunotherapies rapidly and comprehensively. This platform enables rapid testing of multiple cell therapy candidates from various process options against multiple target tumor cells, providing reproducible immune cell characterization and single-cell functional characterization in a fraction of the time needed by existing analytical tools.

KCAS Acquires Flowmetric To Boost Cell And Gene Therapy Capabilities

In July 2022, KCAS Bioanalytical & Biomarker Services, a US-based provider of comprehensive bioanalytical services, acquired FlowMetric LLC for an undisclosed amount. Through this acquisition, KCAS aims to enhance its capabilities in serving cell and gene therapy programs and meet the growing demands of its customers by providing additional operational support to effectively address the increasing industry needs. FlowMetric LLC is a US-based biotechnology company that offers pre-clinical services such as cell sorting, functional analysis of cell signaling, and cell banking outsourcing. North America was the largest region in the cell banking outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell banking outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell banking outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The cell banking outsourcing market includes revenues earned by entities by providing services, such as cell line establishment, cryopreservation, cell line characterization, facilitating the distribution of cell lines, and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cell banking outsourcing market research report is one of a series of new reports from The Business Research Company that provides cell banking outsourcing market statistics, including cell banking outsourcing industry global market size, regional shares, competitors with a cell banking outsourcing market share, detailed cell banking outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the cell banking outsourcing industry. This cell banking outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell Therapy Human Raw Materials Market Definition And Segments

Cell therapy human raw materials are biological substances derived from human sources, such as cells, tissues, and blood components, used as foundational elements in the development and manufacturing of cell-based therapeutic products. These raw materials are employed in various stages of cell therapy production to create treatments for diseases such as cancer, genetic disorders, and degenerative conditions. The main product types of cell therapy human raw materials are cell culture media, cell culture serum, cell culture supplements, reagents and buffers, and others. Cell culture media are solutions that provide nutrients and an environment for cell growth outside their natural setting, which is essential for lab-based cell studies. The products are used for various types of cell therapies, including dendritic cell therapy, natural killer (NK) cell therapy, stem cell therapy, and T-cell therapy, by end users such as biopharmaceutical and pharmaceutical companies, contract research organizations (CROs), and contract manufacturing organizations (CMOs), as well as academic and research institutions. The cell therapy human raw materials market covered in this report is segmented – 1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials 2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy 3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions The cell therapy human raw materials market size has grown exponentially in recent years. It will grow from $2.34 billion in 2023 to $2.81 billion in 2024 at a compound annual growth rate (CAGR) of 20.1%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, high demand for regenerative medicines, governmental funding and support, and growing healthcare expenditure. The cell therapy human raw materials market size is expected to see exponential growth in the next few years. It will grow to $5.86 billion in 2028 at a compound annual growth rate (CAGR) of 20.2%. The growth in the forecast period can be attributed to expanding therapeutic applications, rising patient awareness, favorable regulatory frameworks, a growing biopharmaceutical sector, and improved manufacturing processes. Major trends in the forecast period include the adoption of allogeneic therapies, the integration of artificial intelligence, an increase in off-the-shelf cell therapies, the use of 3D bioprinting technology, and the and the development of hybrid cell therapies.

Rising Adoption Of Regenerative Medicine Is Driving The Cell Therapy Human Raw Materials Market

The rising adoption of regenerative medicine is expected to drive the cell therapy human raw materials market going forward. Regenerative medicine involves harnessing the body's own regenerative capabilities or using external stimuli such as stem cells, tissue engineering, or gene therapy to repair, replace, or regenerate damaged tissues and organs, aiming to restore normal function. Regenerative medicine gains visibility due to advancements in biotechnology, a rise in understanding cellular mechanisms, a growing demand for personalized medicine, and the potential to address unmet medical needs more effectively. Cell therapy and human raw materials facilitate the rising adoption of regenerative medicine by providing the essential biological components necessary for cell-based therapies, enabling the production of standardized and reliable treatments for various medical conditions. For instance, in August 2023, according to a report by the Alliance for Regenerative Medicine, a US-based non-profit organization, there were 2760 cell, gene, and tissue-engineering therapeutic developers worldwide in Q1 2023, up 101% since 1369 in Q1 2022. Moreover, financing for regenerative medicine and advanced therapies in 2021 will reach $22.7 billion, compared to $19.9 billion in 2020. Therefore, the rising adoption of regenerative medicine is driving the cell therapy human raw materials market. Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group Ltd., Grifols S.A., WuXi AppTec, Catalent Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Pall Corporation, Bio-Techne Corporation, Miltenyi Biotec, Actylis, STEMCELL Technologies, Takara Bio Inc., Vericel Corporation, ACROBiosystems, BioIVT LLC, Orgenesis Inc., PromoCell GMBH, ViaCyte Inc., AllCells LLC, Sartorius CellGenix GmbH, Fujifilm Cellular Dynamics Inc., Mesoblast Limited, RoosterBio Inc., Thermogenesis Holdings Inc.

Chemically Defined Mediums For Accelerated Development In The Cell Therapy Human Raw Materials Market

Major companies operating in the cell therapy human raw materials market increasingly focus on developing chemically defined cell culture mediums to accelerate cell therapy development. A cell culture medium is a nutrient-rich solution designed to provide essential nutrients, growth factors, and environmental conditions necessary for cells' in vitro growth and propagation outside their natural environment. For instance, in May 2023, Lonza Group AG, a Switzerland-based healthcare manufacturing organization, launched TheraPEAK T-VIVO Cell Culture Medium. This launch features a chemically defined formulation, serum-free, and animal component-free composition, recombinant proteins, enhanced culture and expansion support, and application assistance, ensuring consistency, safety, and regulatory compliance in cell therapy manufacturing. This medium represents significant technological advancements by eliminating animal components, chemically defined formulation, and regulatory-friendly characteristics, contributing to improved safety, quality, and regulatory compliance.

Thermo Fisher's PeproTech Acquisition Boosts Recombinant Protein Offerings And Market Reach

In January 2022, Thermo Fisher Scientific Inc., a US-based scientific research and laboratory services company, acquired PeproTech Inc. for $1.85 billion. With this acquisition, Thermo Fisher expands its recombinant protein portfolio, aligns with the biosciences business, and strengthens its market position, impacting the cell therapy human raw materials market by enhancing product offerings and market capabilities. PeproTech Inc. is a US-based biotechnology company that manufactures products for life science research, including cytokines, antibodies, and cell culture media. North America was the largest region in the cell therapy human raw materials market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell therapy human raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The cell therapy human raw materials market consists of sales of primary cells, stem cell banks, tissue scaffolds, cryopreservation media, cell separation products, and extracellular matrices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cell therapy human raw materials market research report is one of a series of new reports from The Business Research Company that provides cell therapy human raw materials market statistics, including cell therapy human raw materials industry global market size, regional shares, competitors with an cell therapy human raw materials market share, detailed cell therapy human raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy human raw materials industry. This cell therapy human raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Compound Camphor Ointment Market Definition And Segments

Compound camphor ointment is a topical medication that typically contains camphor as one of its active ingredients, along with other ingredients such as menthol and various carrier agents. Camphor is a natural substance derived from the wood of the camphor tree or synthesized from turpentine oil. It has been used for its analgesic (pain-relieving), antipruritic (anti-itch), and counterirritant properties. The main compound camphor ointments are for internal use and topical use. Internal use of compound camphor ointment refers to the application or ingestion of the ointment within the body. It is distributed through retail pharmacies, hospital pharmacies, and online pharmacies for several applications, including pain relief, anti-itching, fungal infections, and others. The compound camphor ointment market covered in this report is segmented – 1) By Formulation: Internal Use, Topical Use 2) By Distribution: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies 3) By Application: Pain Relief, Anti-Itching, Fungal Infection, Other Applications The compound camphor ointment market size has grown strongly in recent years. It will grow from $2.47 billion in 2023 to $2.61 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to growing preference for topical analgesics, expanding geriatric population, increasing demand for natural remedies. The compound camphor ointment market size is expected to see strong growth in the next few years. It will grow to $3.28 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing prevalence of musculoskeletal disorders, growing aging population, increasing healthcare expenditure, rising preference for traditional medicine. Major trends in the forecast period include innovative formulations, advanced medical technologies, partnerships, and investments.

Rising Prevalence Of Musculoskeletal Disorders Fuels Growth In Compound Camphor Ointment Market

The increasing prevalence of musculoskeletal disorders is expected to propel the growth of the compound camphor ointment market going forward. Musculoskeletal disorders (MSDs) affect the body's muscles, bones, joints, ligaments, tendons, and other soft tissues. Musculoskeletal disorders arise from various factors, often stemming from repetitive motion, poor posture, overuse, and improper lifting techniques. Compound camphor ointment is used to treat pain and inflammation in joints and muscles and has analgesic and anti-inflammatory qualities that make it practical for musculoskeletal problems. For instance, in July 2022, according to the World Health Organization, a Switzerland-based health organization, approximately 1.71 billion people have musculoskeletal conditions worldwide. Furthermore, in October 2023, according to an international study by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, the number of musculoskeletal disorders in the US is projected to increase by 115% from 2020 to 2050, reaching 1.06 billion cases therefore, the increasing prevalence of musculoskeletal disorders is driving the compound camphor ointment market. Major companies operating in the compound camphor ointment market are CVS Health, McKesson, Cigna Corp., Johnson & Johnson, China Resources Sanjiu Medical & Pharmaceutical Co. Ltd., Cipla Limited, Greenbrier International Inc., Mallinckrodt Plc, Emcure Pharmaceuticals Limited, Vi-jon Laboratories, Oriental Aromatics Ltd., Amrutanjan Health Care limited, Delon Laboratories Inc., Mentholatum Company, Frey & Lau GmbH, Indiana botanic gardens, DLC Laboratories Inc., GHC Group LLC, Focus Consumers Health care LLC, Caribe Natural LLc, Emu Joy, Himalaya Wellness Co., AVN Ayurveda Formulations Pvt. Ltd., Ilesol Pharmaceuticals, Thera Wise

Innovation in Topical Pain Relief With Compound Camphor Ointment Market

Major companies operating in the compound camphor ointment market are focused on innovating topical pain relievers to enhance efficacy, improve patient comfort, and address specific consumer needs. Topical pain relievers are medications applied directly to the skin to alleviate pain. They are commonly used to treat musculoskeletal pain. For instance, in July 2021, Aleve, a US-based pharmaceutical company, launched AleveX, a new collection of topical analgesics. The products contain active ingredients such as menthol and camphor and come in various formats, such as pain-relieving lotion, pain-relieving spray, and pain-relieving massaging stainless steel roll-on, providing temporary relief for minor muscle and joint aches with targeted, fast, powerful, and long-lasting application.

Kobayashi Pharmaceutical's Strategic Acquisition Of Focus Consumer Healthcare Highlights TrueNorth's Expertise In Facilitating Growth

In October 2023, Kobayashi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, acquired Focus Consumer Healthcare LLC for an undisclosed amount. The acquisition exemplifies TrueNorth's ability to assist clients in executing strategic transactions that drive growth and create value in the healthcare and consumer products sectors. Focus Consumer Healthcare LLC is a US-based manufacturer of compound camphor ointments. North America was the largest region in compound camphor ointment in 2023.North America is expected to be the fastest-growing region in the forecast period. The regions covered in the compound camphor ointment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the compound camphor ointment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain The compound camphor ointment market consists of sales of cold sore remedies, wart removal ointments, and hemorrhoid relief ointments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The compound camphor ointments market research report is one of a series of new reports from The Business Research Company that provides compound camphor ointments market statistics, including compound camphor ointments industry global market size, regional shares, competitors with a compound camphor ointments market share, detailed compound camphor ointments market segments, market trends, and opportunities, and any further data you may need to thrive in the compound camphor ointments industry. This compound camphor ointments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.